Shamburg News · 8-K filed Nov 12, 2026, 8:10 AM EST

Silence Therapeutics Reports Third Quarter 2026 Financial Results

SLNCF · Silence Therapeutics plc

  • Earnings
  • Acquisition
  • Materiality: high

Silence Therapeutics plc reported a net loss of $12.4 million, or $0.08 per basic and diluted share, for the three months ended September 30, 2026, compared with a net loss of $21.0 million, or $0.15 per share, a year earlier. R&D expenses were $9.3 million and G&A expenses were $4.9 million for the quarter, and cash and cash equivalents were $247.7 million as of September 30, 2026. The filing also references the previously announced definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, expected to close in the first quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-457060.

Written from the filing by Shamburg Markets. Figures are as reported by the company.